Kankakee

CSL Behring Press Releases

02-10-2018
Hemophilia Video

12-05-2017
CSL and Vitaeris Announce Strategic Partnership with Option to Acquire
CSL and Vitaeris announce strategic collaboration to expedite development of clazakizumab as therapeutic option for solid organ transplant rejection More.


10-29-2017
Data on the Preventive Effects of HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]) in Subjects with Very Frequent HAE Attacks Presented by CSL Behring at the 2017 ACAAI Annual Scientific Meeting
Data on the preventive effects of HAEGARDA®, from a subgroup analysis from the Phase III COMPACT trial, presented at ACAAI 2017 Scientific Meeting. More.

10-24-2017
New Data for HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]) to be presented at the 2017 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting
New data being presented at ACAAI Annual meeting highlighting preventive effect of HAEGARDA in HAE patients with a high frequency of attacks. More.

10-12-2017
CSL Behring Trains Employees to Save Lives in Their Communities and Workplace with CPR; AHA Encourages Other Businesses to Do the Same
CSL Behring is taking its workplace wellness initiatives to a whole new level by providing the American Heart Association’s (AHA) Hands-Only™ cardiopulmonary resuscitation (CPR) training to employees. More.

09-28-2017
Patient Groups Sharpen Their Capabilities to Protect Access to Medicines for Treating Rare Bleeding Disorders
The Great Lakes Hemophilia Foundation (GLHF), the New York City Hemophilia Chapter (NYCHC) and the Ohio Bleeding Disorders Council (OBDC) take on complex legislative and public policy issues to ensure patients’ voices are heard in their statehouses. More.

09-28-2017
Japan’s Ministry of Health, Labour and Welfare Approves AFSTYLA® - CSL Behring’s Novel Recombinant Haemophilia A Treatment
Global biotherapeutics leader CSL Behring today announced that Japan’s Ministry of Health, Labor and Welfare (MHLW) has approved AFSTYLA® (hereafter AFSTYLA) [lonoctocog alfa] a recombinant single-chain coagulation factor VIII (rVIII-SingleChain) in patients with haemophilia A (congenital factor VIII deficiency). More.

09-19-2017
CSL Behring Will Help Transform Biotech Education and Research with $4.92 Million Gift to Penn State
Penn State today announced that CSL Behring has committed $4.92 million to Penn State over the next six years to create the multidisciplinary Center of Excellence in Biotechnology, and to revitalize the Shared Fermentation Facility. More.

09-14-2017
CSL Behring Joins Together With Conference Attendees to Make Donation to IPOPI
Immunoglobulin Leader Donates €15,000 to IPOPI International Patient Organisation to Support Primary Immunodeficiency Awareness Initiatives. More.


09-07-2017
CSL Behring Presents New Alpha 1 Antitrypsin Deficiency Treatment Data at Global ERS Congress
CSL Behring presents data and hosts symposium on real life experiences with Alpha-1. More.

09-06-2017
CSL Behring Joins Together With Others Around the World—Sponsoring the 2017 Meeting of the European Society for Immunodeficiencies (ESID)
Immunoglobulins leader, CSL Behring, sponsors ESID meeting and hosts symposium on new developments in secondary antibody deficiency. More.

07-25-2017
HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]) Now Available in the United States for Patients with Hereditary Angioedema
Global biotherapeutics leader CSL Behring announced today that HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]) is now available in the United States. More.

07-21-2017
CSL Behring Receives Orphan-Drug Exclusivity for HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human])
Global biotherapeutics leader CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has granted the Company seven years of orphan-drug exclusivity for HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]), the first and only subcutaneous treatment option for prevention of hereditary angioedema (HAE) attacks. More.

07-19-2017
FDA Accepts CSL Behring’s Supplemental Biologics License Application for Hizentra® Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Indication
CSL Behring today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company’s supplemental Biologics License Application (BLA) for Hizentra® [Immune globulin subcutaneous (Human) 20% liquid] for the treatment for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) as maintenance therapy to prevent relapse of neuromuscular disability and impairment. More.

07-12-2017
New Data Demonstrate Prophylactic Treatment with IDELVION® Reduces Bleed Frequency and Has Potential to Positively Impact Patients with Haemophilia B
CSL Behring today presented data finding that prophylaxis treatment with IDELVION® provides consistently high factor IX levels, resulting in low bleeding rates in both adult and paediatric patients with haemophilia B. More.

07-11-2017
CSL Behring Awards Researchers to Advance Immunoglobulin Therapy in Treating Neurological Disorders
Global biotherapeutics leader CSL Behring today announced at the Peripheral Nerve Society’s annual meeting the winners of its annual Interlaken Leadership Awards. More.

07-10-2017
New Findings Show AFSTYLA® Provides Long-lasting Efficacy without Increased Product Consumption for Prophylactic and On-Demand Treatment of Haemophilia A
CSL Behring today presented data finding treatment with AFSTYLA® may result in low average product consumption without compromising efficacy in both the prophylaxis and on-demand settings. More.

07-06-2017
New Data for Two Leading Haemophilia Medicines -- AFSTYLA® and IDELVION® -- to be Presented at the International Society on Thrombosis and Haemostasis Congress 2017
CSL Behring announced today that it will present new data from its recombinant coagulation factor development programs at the International Society on Thrombosis and Haemostasis (ISTH) Congress 2017 in Berlin, Germany, July 8 – 13, 2017. More.

06-23-2017
FDA Approves HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]), First and Only Subcutaneous Preventive Treatment for Hereditary Angioedema
Global biotherapeutics leader CSL Behring today announced that the U.S. Food and Drug Administration (FDA) has approved HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]), the first and only subcutaneous therapy indicated for routine prophylaxis to prevent hereditary angioedema (HAE) attacks in adolescent and adult patients. More.